Venus Remedies Limited (BOM:526953)
India
· Delayed Price · Currency is INR | Market Cap | 12.17B |
| Revenue (ttm) | 7.03B |
| Net Income (ttm) | 762.85M |
| Shares Out | 13.37M |
| EPS (ttm) | 57.08 |
| PE Ratio | 15.95 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,951 |
| Average Volume | 6,597 |
| Open | 948.80 |
| Previous Close | 938.05 |
| Day's Range | 903.40 - 962.90 |
| 52-Week Range | 295.00 - 1,119.00 |
| Beta | 0.04 |
| RSI | 45.78 |
| Earnings Date | May 26, 2026 |
About Venus Remedies
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, and solvent products, as well as herbal medicine. The c... [Read more]
Financial Performance
In fiscal year 2025, Venus Remedies's revenue was 6.48 billion, an increase of 7.72% compared to the previous year's 6.01 billion. Earnings were 453.15 million, an increase of 59.05%.
Financial StatementsNews
Venus Remedies renews GMP certification from Ukraine’s SMDC for Baddi facility
Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a pharmaceutical manufacturer headquartered in India, has renewed its Good Manufacturing Practices (GMP) certification from the State Service of Uk...
Venus Remedies shares jump 11% after US FDA grants QIDP status to novel antibiotic VRP-034
Shares of Venus Remedies surged over 11% in Wednesday’s trade, climbing to ₹347.65 on the NSE, after the company announced that its novel antibiotic formulation VRP-034 has received Qualified Infectio...
Venus Remedies gets US FDA grants QIDP status to novel polymyxin B formulation VRP-034
Venus Remedies Limited has received a significant regulatory boost with the United States Food and Drug Administration (US FDA) granting Qualified Infectious Disease Product (QIDP) designation to its ...
Venus Remedies secures exclusive rights for MET-X clinical development in India
Venus Remedies Ltd, a renowned Indian pharmaceutical company specializing in antimicrobial resistance (AMR), has entered into an exclusive licensing agreement with UK-based Infex Therapeutics. This co...
Venus Remedies shares surge 10% after EU GMP Certification renewal
Venus Remedies saw its shares jumped 10% after securing the renewal of its European Good Manufacturing Practices (EU GMP) certification from Infarmed, Portugal’s National Authority of Medicines and He...
Venus Remedies successfully renews EU GMP certification, reinforcing its European market presence
Venus Remedies Limited has announced the successful renewal of its European Good Manufacturing Practices (EU GMP) certification. Granted by Infarmed, the National Authority of Medicines and Health Pro...
Venus Remedies stock jumps 4% after receiving GMP certification for Antibiotic facility
Shares of Venus Remedies surged 4% after the company received a Good Manufacturing Practice (GMP) certification from the Ministry of Health of Moldova for its carbapenem antibiotic facility. This cert...
Venus Remedies shares surge 6% on Pemetrexed marketing authorization in Philippines
Venus Remedies’ stock jumped 6% following the announcement of marketing authorization for Pemetrexed 500mg, a chemotherapy agent used to treat lung cancer and mesothelioma, in the Philippines. This ap...